FindTrial
Sign In

Utility of MUC1 in breast carcinoma with clinicopathological parameters, tumor characteristics and hormone receptors.

Utility of MUC1 expression as a prognostic marker in breast carcinoma and its correlation with clinico-pathological parameters, tumor characteristics and hormone receptors.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/02/031221
Enrollment
100
Registered
2021-02-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: MUC1: . MUC1 ,a transmembranemucin has been shown to be involve in several signaling pathway , including Ras, beta-catenin, p120, p53 and estrogen receptor alpha.5 Beta-catenin forms a

Sponsors

Rohilkhand Medical College Bareilly
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All types of breast carcinomabiopsy specimens received in the Pathology Department of Rohilkhand Medical College & Hospital, Bareilly. 2.Cases with complete details like age, sex, histological diagnosis, tumour grade and lymphovascular invasion and other clinical parameters.

Exclusion criteria

Exclusion criteria: 1.Inadequate samples. 2.Improper records and slides.

Design outcomes

Primary

MeasureTime frame
study MUC1 expression in breast carcinoma as a prognostic marker and correlate with clinico-pathological parameters, tumor characteristics and hormone receptors.Timepoint: Nil—

Secondary

MeasureTime frame
correlate the expression of MUC1 in breast carcinoma with the clinico-pathological parameters, characteristics of the tumor and expression of the hormone receptors.Timepoint: Nil—

Countries

India

Contacts

Public ContactShashwat Verma

Rohilkhand Medical College, Bareilly.

drranjan68@gmail.com9412291009

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026